Sinopharm Group 15on Stock Total Asset

X2S1 Stock  EUR 13.10  0.20  1.55%   
SINOPHARM GROUP 15ON fundamentals help investors to digest information that contributes to SINOPHARM GROUP's financial success or failures. It also enables traders to predict the movement of SINOPHARM Stock. The fundamental analysis module provides a way to measure SINOPHARM GROUP's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to SINOPHARM GROUP stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

SINOPHARM GROUP 15ON Company Total Asset Analysis

SINOPHARM GROUP's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Total Asset

 = 

Tangible Assets

+

Intangible Assets

More About Total Asset | All Equity Analysis
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Competition

Based on the latest financial disclosure, SINOPHARM GROUP 15ON has a Total Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Distribution industry. The total asset for all Germany stocks is 100.0% higher than that of the company.

SINOPHARM Total Asset Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SINOPHARM GROUP's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SINOPHARM GROUP could also be used in its relative valuation, which is a method of valuing SINOPHARM GROUP by comparing valuation metrics of similar companies.
SINOPHARM GROUP is currently under evaluation in total asset category among its peers.

SINOPHARM Fundamentals

About SINOPHARM GROUP Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze SINOPHARM GROUP 15ON's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SINOPHARM GROUP using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SINOPHARM GROUP 15ON based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in SINOPHARM Stock

SINOPHARM GROUP financial ratios help investors to determine whether SINOPHARM Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SINOPHARM with respect to the benefits of owning SINOPHARM GROUP security.